Drug Approval | June 28, 2024
Eugia SEZ’s injectable facility gets EIR from USFDA
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
This tie-up will have no impact on any other brands of the company
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
There was no observation related to data integrity reported
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Subscribe To Our Newsletter & Stay Updated
